<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04490564</url>
  </required_header>
  <id_info>
    <org_study_id>CBS-PD-L1a</org_study_id>
    <nct_id>NCT04490564</nct_id>
  </id_info>
  <brief_title>A Clinical Performance Study to Validate the Use of Novel Molecular Diagnostic Assays for the Detection of Cancer Biomarkers in Peripheral Blood and Primary Tumor Tissue of Patients With Recurrent/Metastatic HNSCC, Metastatic NSCLC or Metastatic Melanoma</brief_title>
  <official_title>A Clinical Performance Study to Validate the Use of Novel Molecular Diagnostic Assays for the Detection of Cancer Biomarkers in Peripheral Blood and Primary Tumor Tissue of Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC), Metastatic Non-Small Cell Lung Cancer (NSCLC) or Metastatic Melanoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmassist Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Athens</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pharmassist Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Conventional biopsy and surgical tumor resection are invasive procedures that capture only&#xD;
      one instance of the progression of the tumor. However, the genome of tumor is not static, but&#xD;
      it is constantly altered during treatment.&#xD;
&#xD;
      Liquid biopsy is a non-invasive approach based on the extraction of information through&#xD;
      peripheral blood analysis. It makes it possible to characterize the development of a solid&#xD;
      tumor in real time, through detailed molecular analysis of circulating genetic material in&#xD;
      peripheral blood.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 25, 2019</start_date>
  <completion_date type="Anticipated">December 25, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 25, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical performance of PD-L1 kit in CTCs of peripheral blood and tumor tissue samples</measure>
    <time_frame>12 months</time_frame>
    <description>The performance of PD-L1 kit at baseline in CTCs (using IF as reference method) and tumor tissue samples (using IHC as reference method) will be assessed via Sensitivity, Specificity, Positive and Negative Predictive Values, Positive and Negative Likelihood Ratios, Accuracy and Diagnostic Odds Ratio.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To study correlations between PD-L1 expression in serial liquid samples with patients' responsiveness to therapy.</measure>
    <time_frame>18 months</time_frame>
    <description>Clinical response to the selected treatment (CR, PR, SD, PD)&#xD;
Survival status</description>
  </secondary_outcome>
  <other_outcome>
    <measure>To study mutation status of BRAF gene in tumor tissue samples and blood samples (CTC, plasma ctDNA) of metastatic melanoma patients</measure>
    <time_frame>18 months</time_frame>
    <description>Mutation profile of BRAF in CTCs, plasma-ctDNA and tumor tissues of metastatic melanoma patients will be evaluated using PCR-molecular assays</description>
  </other_outcome>
  <other_outcome>
    <measure>To study the presence of biomarkers in tumor tissue and blood liquid biopsy samples (at baseline).</measure>
    <time_frame>18 months</time_frame>
    <description>Molecular profile of cancer biomarkers in tumor tissue and peripheral blood samples will be evaluated using PCR-molecular assays</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">185</enrollment>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>HNSCC, NSCLC, melanoma Patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <description>In case of healhty volunteers, only peripheral blood samples will be collected.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>PD-L1 Kit</intervention_name>
    <description>Clinical performance of PD-L1 kit in CTCs of peripheral blood and tumor tissue samples</description>
    <arm_group_label>HNSCC, NSCLC, melanoma Patients</arm_group_label>
    <arm_group_label>Healthy volunteers</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        155 subjects as follows: 25 patients with metastatic/recurrent HNSCC 120 patients with&#xD;
        metastatic NSCLC 10 patients with metastatic melanoma 30 healthy subjects&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female aged ≥ 18 years of age.&#xD;
&#xD;
          2. Patients with a diagnosis of&#xD;
&#xD;
               1. recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), who are&#xD;
                  going to receive PD-1 inhibitor nivolumab OR&#xD;
&#xD;
               2. metastatic Non-Small Cell Lung Cancer (NSCLC), who are going to receive PD-1&#xD;
                  inhibitor, e.g. nivolumab, pembrolizumab,OR&#xD;
&#xD;
               3. metastatic melanoma, who are going to receive to receive PD-1 inhibitor, e.g.&#xD;
                  nivolumab, pembrolizumab.&#xD;
&#xD;
          3. Available tumor tissue sample for immunohistochemical and molecular analysis.&#xD;
&#xD;
          4. Life expectancy ≥ 4 months.&#xD;
&#xD;
          5. Signed informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Male or female younger than 18 years old.&#xD;
&#xD;
          2. History of another malignancy within 3 years or current 2nd primary malignancy.&#xD;
&#xD;
          3. Patients that have not signed the informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sotiria Thoracic Diseases Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <state>Attica</state>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Medical Director</last_name>
      <phone>21 0776 3100</phone>
      <email>manager@sotiria.gr</email>
    </contact>
    <investigator>
      <last_name>Aimilia Tsaroucha</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aretaieio University Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <state>Attica</state>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Medical Director</last_name>
      <phone>21 0728 6000</phone>
      <email>info@aretaeio.com</email>
    </contact>
    <investigator>
      <last_name>Evangelos Bournakis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Athens Attikon</name>
      <address>
        <city>Athens</city>
        <state>Attika</state>
        <zip>124 62</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Medical Director</last_name>
      <phone>0030 210 5831000</phone>
      <email>secrmeddir@attikonhospital.gr</email>
    </contact>
    <investigator>
      <last_name>Amanda Psyrri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bioclinic</name>
      <address>
        <city>Thessaloníki</city>
        <state>Thessaloniki</state>
        <zip>546 22</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Medical Director</last_name>
      <phone>2310 372600</phone>
      <email>the.bioclinic@bioclinic.gr</email>
    </contact>
    <investigator>
      <last_name>Ioannis Boukovinas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Alexandroupoli</name>
      <address>
        <city>Alexandroupolis</city>
        <zip>68100</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Medical Director</last_name>
      <phone>25513 51000</phone>
      <email>nfopgna@pgna.gr</email>
    </contact>
    <investigator>
      <last_name>Stylianos Kakolyris, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Metropolital Hospital</name>
      <address>
        <city>Piraeus</city>
        <zip>18547</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Medical Director</last_name>
      <phone>210 48 09 000</phone>
      <email>information@metropolitan-hospital.gr</email>
    </contact>
    <investigator>
      <last_name>Helena Linardou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 20, 2020</study_first_submitted>
  <study_first_submitted_qc>July 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2020</study_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Liquid biopsy</keyword>
  <keyword>CTC</keyword>
  <keyword>PD-L1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

